Yaoqiu Zhu
Overview
Explore the profile of Yaoqiu Zhu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
162
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhu Y, Zhou J, Romero E
Bioorg Med Chem Lett
. 2022 Jul;
72:128872.
PMID: 35777717
The serendipitous prodrug clopidogrel (CPG, M0) is the mainstay antiplatelet drug in clinical use. The thiophene moiety of CPG undergoes ring opening to form the active metabolite (M13) through two...
2.
Zhu Y, Romero E, Ren X, Sanca A, Du C, Liu C, et al.
Nat Commun
. 2018 Oct;
9(1):4278.
PMID: 30305639
The original version of this Article contained an error in the spelling of the author Bin Geng, which was incorrectly given as Bing Geng. This has been corrected in both...
3.
Zhu Y, Romero E, Ren X, Sanca A, Du C, Liu C, et al.
Nat Commun
. 2018 Sep;
9(1):3952.
PMID: 30262863
Hydrogen sulfide has emerged as a critical endogenous signaling transmitter and a potentially versatile therapeutic agent. The key challenges in this field include the lack of approved hydrogen sulfide-releasing probes...
4.
Zhang Y, Benmohamed R, Zhang W, Kim J, Edgerly C, Zhu Y, et al.
ACS Med Chem Lett
. 2017 Mar;
8(3):377.
PMID: 28337334
[This corrects the article DOI: 10.1021/ml3000963.].
5.
Zhu Y, Zhou J, Jiao B
ACS Med Chem Lett
. 2014 Jun;
4(3):349-52.
PMID: 24900671
Clopidogrel (CPG) is an antithrombotic prodrug that needs hepatic cytochrome P450 (CYP) enzymes for its bioactivation. The clinical effects of CPG have been associated with high intersubject variability and a...
6.
Zhu Y, Zhou J
ACS Med Chem Lett
. 2014 Jun;
3(10):844-9.
PMID: 24900388
The clinical response to the antiplatelet prodrug clopidogrel is associated with high intersubject variability and a certain level of therapeutic resistance. Previous studies have suggested that genetic polymorphism of CYP2C19...
7.
Zhu Y, Zhou J
Chem Res Toxicol
. 2012 Dec;
26(1):179-90.
PMID: 23249383
The biotransformation of clopidogrel has been under extensive investigation to address the observed high clinical variability and resistance of its antithrombotic prodrug therapy. Clopidogrel (M0) is first activated to its...
8.
Zhang Y, Benmohamed R, Zhang W, Kim J, Edgerly C, Zhu Y, et al.
ACS Med Chem Lett
. 2012 Jul;
3(7):584-587.
PMID: 22837812
Cyclohexane 1,3-diones were identified as a class of molecules exhibiting a protective effect against mutant SOD1 induced toxicity in PC-12 cells, but an optimized analogue had little or no effect...
9.
Shan J, Zhang B, Zhu Y, Jiao B, Zheng W, Qi X, et al.
J Med Chem
. 2012 Mar;
55(7):3342-52.
PMID: 22428882
A series of optically active 2-hydroxytetrahydrothienopyridine derivatives were designed and synthesized as prodrugs of clopidogrel thiolactone in order to overcome clopidogrel resistance. The final compounds were evaluated for their inhibitory...
10.
Zhu Y, Silverman R
Biochemistry
. 2008 Feb;
47(8):2231-43.
PMID: 18237198
Despite the essential biological importance of reactions that involve heme, mechanisms of heme reactions in enzymes like nitric oxide synthase (NOS), heme oxygenase (HO), and cytochrome P450s (CYP450s) are still...